348 Index Name Paper ref. Name Paper ref. Liu, A Thu 092 Liu, Ailin Mon 034 Liu, A-J PL22, Mon 330 Liu, AL Tue 365 Liu, C Thu 184, Wed 093 Liu, C-F Mon 354 Liu, C-H Wed 286 Liu, C-Z Thu 199 Liu, C-L Thu 297 Liu, D Thu 298, Tue 158, Wed 362, Wed 258, Tue 036 Liu, G Tue 094, Liu, G-L Mon 031 Liu, H Thu 306, Thu 369 Liu, J FC16.4.5, Mon 323, Tue 076, Tue 458, Wed 336, Thu 116, Thu 340 Liu, JTC YI.06 Liu, J Thu 299 Liu, J-J Tue 159 Liu, J-X Thu 376, Mon 209 Liu, K Tue 272, Mon 077, Mon 078, Mon 329, Thu 275 Liu, K Mon 035 Liu, L FC12.4.5 FC08.1.6 Liu, LL Wed 291 Liu, M Thu 403 Liu, P Mon 434 Liu, P FC06.4.2 Liu, P Thu 300 Liu, Q Mon 434 Liu, Q-C FC16.5.5 Liu, Q-R Thu 176 Liu, R Mon 329, Mon 433, Tue 297 Liu, S Tue 139 Liu, W Tue 269, Tue 035 Liu, X Tue 299, Mon 468, Mon 469, Mon 330, Thu 378 Liu, X-C Mon 172 Liu, Y FC14.5.4, FC06.4.6, Mon 077, Mon 078, Tue 059, Wed 429, Thu 017, Thu 268, Liu, Y-L Tue 083 Liu, Y Mon 331 Liu, Y-L Wed 430 Livesey, MR FC03.3.5 Llerana, A W16.3 Llor, C FC13.1.5 Lloret Linares, C FC01.4.4 Lluel, P Tue 205, Tue 206, Tue 204, Mon 244, Tue 203 Lo, A Tue 196 Lo, TWC Tue 139 Lo, Y-C Thu 301 Locht, LJ Tue 359 Löf, Cr Thu 079 Loftus, L Tue 107 Loga-Zec, S Wed 199 Logothetis, N W33.2 Loh, HH Tue 135 Lohse, MJ Wed 026 Loilier, M Mon 362 Loirat, C FC10.5.5 Loke, AC Wed 431 Loland, C Mon 058 Loland, CJ FC02.3.5, Mon 073 Lonka, L Mon 341 Lönngren, T PL21 Lopaschuk, GD FC05.2.6 Lopes, C Tue 257, Wed 214 Lopes, LR Wed 233, Wed 237 Lopes, MC Tue 397, Mon 291 Lopes, MTP Wed 302 López, E Mon 128 Lopez, EG Mon 038 López, GJ Mon 125 López, M Tue 420, Tue 042 López, MG Mon 079 Lopez, P Wed 209 Lopez-Durán, JL Tue 348 López-Guerrero, JJ Wed 049 López-Islas, I Thu 265 Lopez-Nevot, MA Tue 123 López-Sánchez, P Wed 049 Lopez-Villodres, JA Mon 278, Tue 116, Wed 250, Thu 246 Lorente, JA Thu 235 Lorigados, CB Wed 204, Wed 203, Mon 257 Lorrio, S Mon 079 Lösle, M Thu 098 Lötsch, J FC13.5.3 Lotufo, C FC03.1.5 Lou, Y Thu 445, Thu 089 Louback, L Thu 212 Lovasz, N Wed 101 Lovenberg, T Wed 093 Lovinger, DM Thu 190 Lovrek, M Tue 437 Lovriæ, M Wed 398 Lovric, M Tue 304 Lowry, C A FC17.4.1 Lozano, M Wed 352 Lozinskaya, L Mon 133 Lozoya-Moreno, G Mon 009 Lu, H Mon 228 Lu, L Mon 445 Lu, M-L Wed 430 Lu, P FC07.2.5 Lu, PH Mon 249 Lu, Q Tue 399 Lu, RB Mon 356 Lu, S-C Wed 430 Lu, SM Mon 266 Lu, XH Tue 365 Lu, X-Q FC14.5.4 Lu, Y Mon 092 Lu, YF Thu 116 Lu, Y-F Tue 458, Thu 186, Thu 184, Thu 182, Thu 185 Luan, H Tue 419 Lubbe, M Tue 110, Mon 026 Ls, G FC17.2.5 Ls, S Tue 080 Lucena, MI Wed 109 Lucenteforte, E Thu 302 Lucero, ML Mon 080 Lucero, ML Mon 254 Luciani, S Thu 360
Name Paper ref. Name Paper ref. Lue, S-I Wed 439 Luescher, TF FC16.1.2 Lütjohann, D Tue 045 Lugovkina, T Wed 110 Lukacs, P Mon 218, Mon 217 Lukas, J Tue 197 Lukas, JC Mon 229, Wed 111 Lukaskova, J Tue 137 Lukasova, M Wed 056 Luksha, L Thu 256 Lumlerdkij, A Thu 335 Lumlerdkj, A Thu 361 Lund Nielsen, P Mon 142 Lund, S Mon 154, Tue 132 Lundberg, MH Thu 200, Thu 238 Lunder, M Thu 359, Thu 293 Lundmark, J FC14.1.6 Lundström, L Wed 094 Luo, Dali Thu 390 Luo, G Wed 378 Luo, G FC16.4.4 Luo, J-D Mon 186, FC09.5.6 Luo, Y FC06.4.6 Luo, Y Mon 434 Luoto, P Mon 256 Lupi, P Thu 302 Lupp, A Tue 219 Lutsar, I FC10.3.6 Luviano, A Tue 420 Lv, Y Wed 346 Ly, K Wed 057 Lyhne, NM Tue 358 Lynagh, S Wed 132, Tue 160 Lynagh, T Tue 037 Lynch, J Tue 037 Lynch, K Tue 410, Wed 076 Lyngsøe, C Wed 036 Lyoussi, B W27.2 M. Carnero, MC Tue 144 M. I, H Wed 441 Ma, B Tue 426 Ma, HI Tue 135 Ma, J Thu 295 Ma, Lin Lin Thu 173 Ma, Q Tue 004 Ma, X FC13.2.1, Thu 340 MA, Z Tue 419 Maarsingh, H Wed 095 Mabley, J Mon 157, Wed 096 MacDonald, E Mon 476 Macdonald, T Wed 076 MacDougall, IJA Mon 394 Macedo, A Thu 218, Macedo, AF Mon 126 Macedo, T Wed 180, Wed 140 Macek, K Tue 342, Thu 168 Machado, MA Tue 243 Machado, MM Wed 339 Machida, T Mon 309, Thu 201 Macias, D Mon 129 Maciulaitis, R Tue 329 Mackovicova, K Thu 097 MacLeod, S W36.1 Macolic-Sarinic, V Mon 342, Mon 343, Mon 370, Wed 112 Macugova, A Tue 113 Madazli, R Thu 266 Maddahi, A Tue 220 Maddison, J Tue 327, Tue 322, Wed 113 Madjarevic, T Tue 095 Madsen, J Mon 227 Madsen, KL YI.10 Madura, J Tue 059 Madureira, R Thu 408 Maechler, P Wed 447 Maeda, A Thu 109, Mon 416 Maeda, S Mon 435, Mon 440, Wed 067, Wed 075 Maeda, Y Mon 250, Tue 263 Maekawa, T Thu 268 Maes, L Thu 366 Magalhães, MH Mon 010 Magalhães-Cardoso, T FC08.2.6 Magina, S Wed 114 Maglajlic, JA Wed 171 Magour, S Mon 245 Maguire, JJ W14.3 Magyar, I Mon 436 Mahé, I Tue 188 Maher, J Wed 096 Maheux, J FC17.4.6 Mahmoudi, G Mon 437 Mahmoudian, M Thu 100 Mahmud, FH FC10.2.5 Maier, C W03.6 Maihöfner, C W03.6 Mainz, J Tue 356, Tue 357 Maitra, R Thu 021, Tue 221 Maïzi, H Mon 132 Majzoob Zanjani, S Mon 455 Mak, JCW Wed 218 Mak, JW Thu 379, Thu 380 Mak, TW YI.06 Mak, VWL Tue 139 Makar-Ausperger, K Mon 373, Tue 328, Mon 135 Makarenko, O Mon 087 Mäkilä, E Thu 170, Tue 032 Makonnen, E FC01.4.7, Mon 018 Maksimovic-Ivanic, D FC16.3.6 Makvandi, M Tue 251 Mala, E Tue 222, Tue 421, Tue 240 Malan, SF Mon 442 Malashenko, EA Thu 253 Maldonado Espinza, A Thu 330 Maleki-Dizaji, N Mon 294 Tue 164 Maleki-Dizaji, N Tue 223 Malhotra, B Mon 236, Mon 251 Mali, A Mon 256 Malita, IM Tue 102 Malkin, B Wed 013 Mallal, S FC13.3.1 Mallayasamy, SR FC04.3.7 Malm, T W21.3 Malone, D Thu 191 Malone, DT Wed 428 Malthery, Y Tue 118 Mamadou, G Tue 040 Index 349
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267:
FC15 Endothelium in health and dise
- Page 268 and 269:
W30 Is eNOS Still a valid therapeut
- Page 270 and 271:
FC16 Natural products: Past and fut
- Page 272 and 273:
FC16 Natural products: Past and fut
- Page 274 and 275:
FC16 Natural products: Past and fut
- Page 276 and 277:
FC17 New approaches and targets in
- Page 278 and 279:
FC17 New approaches and targets in
- Page 280 and 281:
W34 State-of-the-art of basic and c
- Page 282 and 283:
FC10 Drugs for half the world: Paed
- Page 284 and 285:
FC11 G protein-coupled 7TM receptor
- Page 286 and 287:
FC11 G protein-coupled 7TM receptor
- Page 288 and 289:
FC11 G protein-coupled 7TM receptor
- Page 290 and 291:
FC13 Maximising benefits and minimi
- Page 292 and 293:
FC13 Maximising benefits and minimi
- Page 294 and 295:
W29 New horizons in therapeutic dru
- Page 296 and 297:
FC14 Addiction and doping: Neurobio
- Page 298 and 299:
FC15 Endothelium in health and dise
- Page 300 and 301: FC15 Endothelium in health and dise
- Page 302 and 303: FC15 Endothelium in health and dise
- Page 304 and 305: FC16 Natural products: Past and fut
- Page 306 and 307: FC16 Natural products: Past and fut
- Page 308 and 309: FC16 Natural products: Past and fut
- Page 310 and 311: FC16 Natural products: Past and fut
- Page 312 and 313: FC17 New approaches and targets in
- Page 314 and 315: FC18 Nuclear receptor targets for t
- Page 316 and 317: 314 Index Name Paper ref. Name Pape
- Page 318 and 319: 316 Index Name Paper ref. Name Pape
- Page 320 and 321: 318 Index Name Paper ref. Name Pape
- Page 322 and 323: 320 Index Name Paper ref. Name Pape
- Page 324 and 325: 322 Index Name Paper ref. Name Pape
- Page 326 and 327: 324 Index Name Paper ref. Name Pape
- Page 328 and 329: 326 Index Name Paper ref. Name Pape
- Page 330 and 331: 328 Index Name Paper ref. Name Pape
- Page 332 and 333: 330 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 338 and 339: 336 Index Name Paper ref. Name Pape
- Page 340 and 341: 338 Index Name Paper ref. Name Pape
- Page 342 and 343: 340 Index Name Paper ref. Name Pape
- Page 344 and 345: 342 Index Name Paper ref. Name Pape
- Page 346 and 347: 344 Index Name Paper ref. Name Pape
- Page 348 and 349: 346 Index Name Paper ref. Name Pape
- Page 352 and 353: 350 Index Name Paper ref. Name Pape
- Page 354 and 355: 352 Index Name Paper ref. Name Pape
- Page 356 and 357: 354 Index Name Paper ref. Name Pape
- Page 358 and 359: 356 Index Name Paper ref. Name Pape
- Page 360 and 361: 358 Index Name Paper ref. Name Pape
- Page 362 and 363: 360 Index Name Paper ref. Name Pape
- Page 364 and 365: 362 Index Name Paper ref. Name Pape
- Page 366 and 367: 364 Index Name Paper ref. Name Pape
- Page 368 and 369: 366 Index Name Paper ref. Name Pape
- Page 370 and 371: 368 Index Name Paper ref. Name Pape
- Page 372 and 373: 370 Index Name Paper ref. Name Pape
- Page 374 and 375: 372 Index Name Paper ref. Name Pape
- Page 376 and 377: 374 Index Name Paper ref. Name Pape
- Page 378 and 379: 376 Index Name Paper ref. Name Pape
- Page 380 and 381: 378 Index Name Paper ref. Name Pape
- Page 382 and 383: 380 Index Name Paper ref. Name Pape
- Page 384 and 385: 382 Notes Notes
- Page 386: Final Programme printed in Singapor